EA201991729A1 - Антитела к tgf-бета и их применение - Google Patents
Антитела к tgf-бета и их применениеInfo
- Publication number
- EA201991729A1 EA201991729A1 EA201991729A EA201991729A EA201991729A1 EA 201991729 A1 EA201991729 A1 EA 201991729A1 EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A EA201991729 A EA 201991729A EA 201991729 A1 EA201991729 A1 EA 201991729A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tgf
- antibodies
- beta
- application
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305061 | 2017-01-20 | ||
PCT/IB2018/000088 WO2018134681A1 (fr) | 2017-01-20 | 2018-01-19 | Anticorps anti-tgf-bêta et leur utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991729A1 true EA201991729A1 (ru) | 2019-12-30 |
Family
ID=58018036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991729A EA201991729A1 (ru) | 2017-01-20 | 2018-01-19 | Антитела к tgf-бета и их применение |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3571227A1 (fr) |
EA (1) | EA201991729A1 (fr) |
WO (1) | WO2018134681A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
CN112703038A (zh) | 2018-07-10 | 2021-04-23 | 赛诺菲 | 靶向CD38和TGF-β的抗癌组合疗法 |
CA3128042A1 (fr) | 2019-01-30 | 2020-08-06 | Scholar Rock, Inc. | Inhibiteurs specifiques du complexe ltbp de tgfs et leurs utilisations |
KR20220139888A (ko) | 2020-01-11 | 2022-10-17 | 스칼러 락, 인크. | TGFβ 억제제 및 그의 용도 |
JP2023511255A (ja) | 2020-01-11 | 2023-03-17 | スカラー ロック インコーポレイテッド | TGF-β阻害剤及びその使用 |
MX2022011455A (es) * | 2020-03-19 | 2022-10-03 | Genentech Inc | Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso. |
WO2022204581A2 (fr) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Inhibiteurs de tgf-bêta et leur utilisation |
TW202304979A (zh) * | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
EP4348260A2 (fr) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Inhibiteurs de tgf-bêta et leur utilisation thérapeutique |
WO2023288277A1 (fr) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Inhibiteurs spécifiques du complexe ltbp de tgfb1 et leurs utilisations |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060286105A1 (en) | 2003-04-30 | 2006-12-21 | Steven Ledbetter | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
HUE042689T2 (hu) | 2005-02-08 | 2019-07-29 | Genzyme Corp | TGFbéta elleni antitestek |
SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind B7-H1 and PD-1 |
WO2014153435A1 (fr) * | 2013-03-20 | 2014-09-25 | Genzyme Corporation | Méthodes de traitement de l'ostéogenèse imparfaite |
MX2016003292A (es) | 2013-09-13 | 2016-06-24 | Beigene Ltd | Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos. |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
BR112017007379A2 (pt) * | 2014-10-14 | 2017-12-19 | Dana Farber Cancer Inst Inc | moléculas de anticorpo para pd-l1 e usos das mesmas |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
CN108136001B (zh) * | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
-
2018
- 2018-01-19 EP EP18711394.9A patent/EP3571227A1/fr active Pending
- 2018-01-19 WO PCT/IB2018/000088 patent/WO2018134681A1/fr unknown
- 2018-01-19 EA EA201991729A patent/EA201991729A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
EP3571227A1 (fr) | 2019-11-27 |
WO2018134681A1 (fr) | 2018-07-26 |
WO2018134681A8 (fr) | 2019-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991729A1 (ru) | Антитела к tgf-бета и их применение | |
EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
MD3303379T2 (ro) | Agenți de legare TIGIT și utilizări ale acestora | |
EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
EA201990208A1 (ru) | Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EA201891992A1 (ru) | Химерные рецепторы и способы их применения | |
PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
MX2023002588A (es) | Anticuerpos anti-tgf-beta y su uso. | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
MX2019005426A (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
EA201790288A1 (ru) | Анти-ctla4 моноклональное антитело или его антигенсвязывающий фрагмент, фармацевтическая композиция и применение | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201890443A1 (ru) | Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение | |
EA201790248A1 (ru) | Композиции носитель-антитело и способы их получения и применения | |
PE20161390A1 (es) | Anticuerpos multiespecificos | |
EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
EA201791590A1 (ru) | Антитела к tau и их применение | |
EA201691541A1 (ru) | Новые анти-baff антитела | |
EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
EA201992460A1 (ru) | Антитела-агонисты btla и их применение | |
EA201792561A1 (ru) | Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения |